Literature DB >> 95187

Isoprinosine increases the antitumor action of interferon.

I Cerutti, C Chany, J F Schlumberger.   

Abstract

The association of relatively low doses of interferon with an immunostimulant, isoprinosine, enhanced the antitumor effect of interferon. Each mouse was inoculated with 10(6) Crocker Tumor 180/TG cells. The best results were obtained when both interferon and isoprinosine were injected three times a week for 1 month. Under these conditions, the mean survival time increased from 26 days in the controls to 45 days in the interferon-treated group to 64 days when both agents were used. Isoprinosine alone had no effect. The final survival rate increased from 1 mouse out of 50 mice in the control group to 10 mice out of 50 in the interferon-treated groups and to 25 mice out of 50 with the combined treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 95187     DOI: 10.1016/0192-0561(79)90031-6

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

1.  Potentiation by levamisole, methisoprinol, and adenine or adenosine of the inhibitory activity of human interferon against encephalomyocarditis virus.

Authors:  A Muñoz; R A García; A Pérez-Aranda
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Coordinated therapeutic effects of immune modulators and interferon.

Authors:  I Cerutti; C Chany
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

3.  Isoprinosine delays the early appearance of autoimmunity in NZB/NZW F1 mice treated with interferon.

Authors:  D Sergiescu; I Cerutti; A Kahan; D Piatier; E Efthymiou
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

4.  Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases.

Authors:  T Nakamura; N Miyasaka; R M Pope; N Talal; I J Russell
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

5.  Interferon effect on cytolytic T lymphocytes in a single cycle assay.

Authors:  M Bergeret; M Fouchard; A Gregoire; C Chany; D Zagury
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

Review 6.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.